SAN DIEGO, Aug. 7 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals,
Inc. (Nasdaq: AMLN) today announced that on August 7, 2007, it filed with
the Securities and Exchange Commission (the "SEC") a resale registration
statement on Form S-3 (the "Registration Statement") that was effective
immediately upon filing with the SEC. Amylin filed the Registration
Statement to satisfy certain of its obligations under a registration rights
agreement that Amylin entered into in connection with its recent private
placement of $575 million in aggregate principal amount of 3.0% convertible
senior notes due 2014. The Registration Statement, while effective, allows
selling securityholders to publicly resell the convertible senior notes and
the common stock issuable upon their conversion, subject to certain
limitations included in the registration rights agreement and the
satisfaction by selling securityholders of the prospectus delivery
requirements of the Securities Act of 1933, as amended (the "Securities
Act"), in connection with any such resales.
A written prospectus meeting the requirements of Section 10 of the
Securities Act may be obtained from Amylin at 9360 Towne Centre Drive, San
Diego, California 92121, Attention: General Counsel.
This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act and Section 21E of the
Securities Exchange Act of 1934, as amended. In particular, selling
securityholders may only use the resale registration statement for resales
of their securities while it remains effective and subject to the
satisfaction of certain other conditions.
About Amylin
Amylin Pharmaceuticals is a biopharmaceutical company committed to
improving lives through the discovery, development and commercialization of
innovative medicines. Amylin has developed and gained approval for two
first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate)
injection and BYETTA(R) (exenatide) injection. Amylin's research and
development activities leverage the company's expertise in metabolism to
develop potential therapies to treat diabetes and obesity. Amylin is
located in San Diego, California with over 1,700 employees nationwide.
Further information on Amylin Pharmaceuticals and its pipeline in
metabolism is available at http://www.amylin.com.
SOURCE Amylin Pharmaceuticals, Inc.
 back to top
Related links:
http://www.amylin.com
CONTACT:
Mark G. Foletta, Senior Vice President of
Finance and Chief Financial Officer of Amylin Pharmaceuticals,
Inc., +1-858-552-2200
|
